Cincinnati Children’s
VC Fund
Cincinnati, United States
Cincinnati Children’s is a VC fund in Cincinnati focused on Health Care and Biotechnology. Patients and families from across the region and around the world come to Cincinnati Children’s Hospital Medical Center because we are dedicated to improving child health. Other medical providers often turn to us when a child needs a complex surgical procedure or treatment for a rare pediatric disease. We discover new and better ways to treatthe conditions that affect children, maintaining our status as one of the world’s foremost centers for pediatric care.
- Total investments:
- 11
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries Cincinnati Children’s invests in
Stages Cincinnati Children’s invests in
Countries Cincinnati Children’s invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Andrew Herr
|
|||
David Moore
|
|||
James Heubi
|
|||
Margaret Collins
|
|||
Margaret Hostetter
|
|||
| See all 6 contacts → | |||
Investment Focus
Industry
- Health Care 5 (45%)
- Biotechnology 3 (27%)
- Medical Device 3 (27%)
- Pharmaceutical 3 (27%)
- Medical 1 (9%)
Stage
- Series C 4 (36%)
- Series A 2 (18%)
- Series B 2 (18%)
- Series D 1 (9%)
- Funding Round 1 (9%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Andrew Herr
Director of Admissions, Immunology PhD Progam; Professor
|
Director of Admissions, Immunology PhD Progam; Professor | Total investments: 0 | Find email | |
|
David Moore
Director, Communication Scineces Research Center
|
Director, Communication Scineces Research Center | Total investments: 0 | Find email | |
|
James Heubi
Professor of Department of Pediatrics
|
Professor of Department of Pediatrics | Total investments: 0 | Find email | |
|
Margaret Collins
Professor of Pediatrics & Pathologist
|
Professor of Pediatrics & Pathologist | Total investments: 0 | Find email | |
|
Margaret Hostetter
Professor of Pediatrics; Editor-in-Chief, Current Opinion in Pediatrics
|
Professor of Pediatrics; Editor-in-Chief, Current Opinion in Pediatrics | Total investments: 0 | Find email | |
| See all 6 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Hippocratic AI
|
Hippocratic AI’s Aim is to develop the safest artificial Health General Intelligence (HGI). greatly enhance healthcare access and boost the scalability of healthcare professionals using the safest artificial Health General Intelligence (HGI), resulting in a more fair system of care for all. | $126M / Series C / Nov 03, 2025 | |
|
Hippocratic AI
|
Hippocratic AI’s Aim is to develop the safest artificial Health General Intelligence (HGI). greatly enhance healthcare access and boost the scalability of healthcare professionals using the safest artificial Health General Intelligence (HGI), resulting in a more fair system of care for all. | $53M / Series A / Mar 18, 2024 | |
STAQ Pharma
|
STAQ Pharma offers safety, transparency, availability, and quality to compounded medications. It features Onsite production of non-sterile to sterile solutions. And sterile-to-sterile repackaging. Inventory systems to forecast needs and proactively provide partners with critical products.It was founded in 2018 and headquartered in Denver,Colorado. | Series C / Mar 02, 2022 | |
Enable Injections
|
Enable Injections develops and manufactures wearable drug delivery systems centered on the enFuse platform, a body-worn technology that enables subcutaneous administration of large-volume pharmaceutical and biologic therapies without traditional intravenous methods. The company focuses on engineering devices that allow patients to receive treatmentthrough simple, hands-free injections under the skin while collaborating with pharmaceutical partners to integrate its delivery systems with specific therapies. Its services encompass design, clinical support, manufacturing, and supply of combination products built around the enFuse technology. Enable Injections engages in partnerships to expand application of its delivery systems across varied therapeutic areas and supports regulatory and commercialization planning with its collaborators. | $215M / Series C / Jan 27, 2022 | |
Airway Therapeutics
|
Airway Therapeutics is an early stage development company that is licensing technology from within the pulmonary research program of Cincinnati Children's Hospital Medical Center (CCHMC) for further technology platform development. This platform will enable the development of three or more products that address various market needs in theoverall market for lung disorders. | $15.5M / Series C / Dec 05, 2019 | |
|
Enable Injections
|
Enable Injections develops and manufactures wearable drug delivery systems centered on the enFuse platform, a body-worn technology that enables subcutaneous administration of large-volume pharmaceutical and biologic therapies without traditional intravenous methods. The company focuses on engineering devices that allow patients to receive treatmentthrough simple, hands-free injections under the skin while collaborating with pharmaceutical partners to integrate its delivery systems with specific therapies. Its services encompass design, clinical support, manufacturing, and supply of combination products built around the enFuse technology. Enable Injections engages in partnerships to expand application of its delivery systems across varied therapeutic areas and supports regulatory and commercialization planning with its collaborators. | $50M / Series B / Oct 25, 2018 | |
|
Airway Therapeutics
|
Airway Therapeutics is an early stage development company that is licensing technology from within the pulmonary research program of Cincinnati Children's Hospital Medical Center (CCHMC) for further technology platform development. This platform will enable the development of three or more products that address various market needs in theoverall market for lung disorders. | $10.9M / Series B / Mar 13, 2018 | |
|
Airway Therapeutics
|
Airway Therapeutics is an early stage development company that is licensing technology from within the pulmonary research program of Cincinnati Children's Hospital Medical Center (CCHMC) for further technology platform development. This platform will enable the development of three or more products that address various market needs in theoverall market for lung disorders. | $6.3M / Mar 06, 2017 | |
|
Airway Therapeutics
|
Airway Therapeutics is an early stage development company that is licensing technology from within the pulmonary research program of Cincinnati Children's Hospital Medical Center (CCHMC) for further technology platform development. This platform will enable the development of three or more products that address various market needs in theoverall market for lung disorders. | $6.4M / Convertible Note / Mar 06, 2017 | |
Assurerx Health
|
Assurex Health is a personalized medicine company dedicated to helping clinicians determine the right medication for individual patients with medical conditions. Assurex Health’s proprietary Genesight® technology is based on pharmacogenomics – the study of the genetic factors that influence an individual’s response to drug treatments – as well asevidence-based medicine and clinical pharmacology. | $37.4M / Series D / Dec 23, 2014 | |
| See all 11 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Cincinnati Children’s invest in?
Cincinnati Children’s invests primarily in Health Care, Biotechnology and Medical Device startups, most often at Series C and Series A stage. Most of the 11 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Cincinnati Children’s?
Public channels for Cincinnati Children’s include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Cincinnati Children’s?
The team at Cincinnati Children’s includes Andrew Herr (Director of Admissions, Immunology PhD Progam; Professor), David Moore (Director, Communication Scineces Research Center) and James Heubi (Professor of Department of Pediatrics), among 6 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
